About

Revolutionize Disease Detection with Pepex® Biosensor Technology

Transform healthcare with our advanced biosensor technology, detecting cancer, Alzheimer’s, HIV, and more.

Invest in the next breakthrough company in as little as $500!

About

Pepex® is at the forefront of revolutionizing disease detection and monitoring with our proprietary biosensor technology. Our advanced diagnostics detect biomarkers for cancer, Alzheimer’s, HIV, and more. With over 300 patents and global adoption, we envision a future of universally accessible, personalized healthcare for better outcomes.

What We Do

At Pepex® Biomedical, we specialize in pioneering cutting-edge biosensor technology for healthcare. Our solutions are designed to offer precise and painless monitoring of a wide range of health markers, providing users with invaluable real-time data insights.

Through our PepexCLOUD™ platform, healthcare providers access actionable insights for personalized care, enhancing patient outcomes. Committed to innovation, we shape proactive, preventive, and personalized healthcare worldwide, revolutionizing standards with accessible, impactful medical technology.

Technology

Pepex® Biomedical leads in advanced biosensor technology, providing precise monitoring and real-time insights for proactive healthcare management. Our solutions offer painless tracking and personalized care, revolutionizing healthcare with enhanced outcomes and improved quality of life.

Pepex® Biomedical leads in advanced biosensor technology, providing precise monitoring and real-time insights for proactive healthcare management. Our solutions offer painless tracking and personalized care, revolutionizing healthcare with enhanced outcomes and improved quality of life.

Precision Monitoring and Real-Time Insights

Pepex®’s advanced sensors provide precise monitoring of vital health markers, ensuring accuracy and reliability. Equipped with wireless connectivity, users receive real-time data to proactively manage their health. 

Personalized Care and Enhanced Outcomes

Pepex® Biomedical offers tailored solutions for customized care plans. Real-time insights enable proactive management, improving outcomes. Users enjoy enhanced quality of life, defining a future of precise, convenient healthcare.

PepexCLOUD™ Platform

How It Works

Pepex Biomedical engineered the mTrio® BGM System, an innovative and smart IoT Medical Device to help Payer’s (Insurance Companies) effectively manage Diabetes Population Health and enhance the quality of clinical care, improve patient outcomes and lower payer costs

“With this system, we are empowering Physicians to make the right decision, at the right time and provide precise, personalized care at the time of need to dramatically improve patient compliance and outcomes”

Leadership

At the core of our company is a team of seasoned professionals whose diverse expertise drives our success and innovation. Each leader brings a unique perspective and extensive experience, keeping us at the industry's forefront. Meet the people shaping our future and leading us to new heights.

Paul Danner

Chairman & Chief Executive Officer

Prior to joining Pepex, Mr. Danner successfully marketed service offerings, secured product placement, increased market share, and grown revenue on five continents while affiliated with an array of Fortune 100 organizations, mid-market companies, and start-up ventures. As a senior business leader, he previously served as the Chief Executive Officer of three Nasdaq-listed companies.  Retiring with the rank of Captain, Mr. Danner served as a Naval Aviator flying the F-14 Tomcat, and subsequently as an Aerospace Engineering Duty Officer supporting the Naval Air Systems Command, for 8 years on active duty plus 22 years with the reserve component of the United States Navy.  Mr. Danner earned a Bachelor of Science degree in Business Finance from Colorado State University and holds an MBA degree from the Strome College of Business at Old Dominion University.

Brooke Turk

Chief Financial Officer

Ms. Turk began her career with Arthur Andersen & Co. before progressing quickly to positions of ever-increasing responsibility with Jones Intercable, Qwest Communications International, and Dex Media, a $1.6 Billion, NYSE-listed private equity portfolio company, and others. Since launching her independent consulting practice, Ms. Turk has advised clients in the Construction, Financial, Healthcare, Industrials, Professional Services, Real Estate, and Technology sectors on strategic, financial, and operational improvements.  Ms. Turk earned a Bachelor of Arts degree in Organizational Communication from Western Colorado University and holds a Master of Science degree in Business Administration with an emphasis in Taxation from Colorado State University.

Steven J. Bupp M.D.

Chief Medical Officer & Member of the Board

Dr. Bupp affiliated with Pepex Biomedical as an angel investor in 1999 and became its Medical Director and a Board member in 2012.  During the past 35 years, he has maintained a private Psychiatry/Pharmacology practice, led a community mental health center supporting from 350 to 11,000 patients and was the Principal Investigator in over 45 Phase III FDA sanctioned pharmaceutical drug trials.  He has extensive experience with quality management, operations efficiency, FDA protocols, IT/software development, and business development.  Dr. Bupp received a Bachelor of Arts degree in Psychology from Wichita State University and a Medical Degree from the University of Kansas School of Medicine. He furthered his training with a psychiatry residency followed by a Clinical Pharmacology Fellowship at the University of Kansas School of Medicine-Wichita.

Nathan Long Ph.D

Chief Product Architect/Founder

Dr. Long has extensive technical expertise in nanotechnology, biosensors, bioenergy, data analytics and new business incubation.  He formerly served as the Chief Executive Officer of Pepex Biomedical, Central Michigan University Research Corporation, and Bio-Nano Power.  Before moving into senior business leadership roles, he led technical development teams for Colgate-Palmolive, BASF/Diversey Wyandotte, and Benckiser Consumer Products, collectively launching over 200 new products.  Having been granted many U.S. and international patents in biosensor structures and nanotechnology, he is now leading the Company’s product development and commercialization programs. Dr. Long earned a Bachelor of Science degree in Chemistry from the University of Michigan and a PhD in Organic Chemistry from Michigan State University.

Vojtech Svoboda Ph.D

Chief Science Officer

Vojtech Svoboda has over 20 years of experience with research and development of electrochemical systems including biosensors.  Dr. Svoboda holds a master’s degree and PhD degrees in electrical engineering/electrochemistry and gained extensive work experience and expertise at various European and American academic and industrial research institutions.  As a principal investigator, he has completed numerous governmental grant-funded research projects.  Dr. Svoboda has also served as a reviewer on the National Science Foundation biosensing panel, and at multiple peer-reviewed journals.  He previously taught applied electrochemistry classes at the University of Alabama in Huntsville and was most recently affiliated with the Georgia Institute of Technology as a visiting professor.

James Say

Chief Engineer Emeritus

Mr. Say was an early engineering collaborator with Professor Adam Heller at the University of Texas – Austin during the time when Dr. Heller developed the WiredEnzymeTM chemistry.  He was the conceptual designer and lead engineer at E. Heller & company, and later TheraSense, Inc., during the initial development of patented structures and systems used in the original FreestyleTM blood glucose diagnostic product.  In 2004, TheraSense was acquired by Abbott Laboratories for $1.2 billion, and their diabetes care division currently reports annualized revenue over $5 billion, primarily from the sale of its family of FreestyleTM LibreTM products.  Mr. Say has been granted over 200 patents in biosensor structures and systems and continues to advise the Company on its quest to become a leading industry contract development and manufacturing organization source for electrochemical biosensors.

Brenda Simpson DNP, RN

Independent Director

Dr. Simpson is currently the Senior Vice President & Chief Nursing Officer for CommonSpirit Health – Mountain Region, formally Centura Health. Supporting nearly 6,500 nurses across 20 hospitals and 260 clinics in three states, she is responsible for managing and evaluating system-wide clinical policies and the nursing shared governance framework, nursing professional development and the Central Staffing Office.  With more than 25 years of progressive leadership experience, Dr. Simpson previously served as the senior nurse executive for Northeast Georgia Health System and CHI St. Vincent Health System. Dr. Simpson earned a Bachelor of Science in Nursing from Tennessee State University, a Master of Science degree in Nursing from the University of Tennessee, and a Doctor of Nursing Practice degree from the University of South Alabama.

Soren Christiansen M.D.

Independent Director

Prior to joining Pepex, Dr. Christiansen’s concluded an esteemed career with Merck & Co. Inc. spanning 30 years with assignments worldwide.  His executive assignments included Senior Vice President of Merck Vaccines/Head of the Global Commercial division, and President for Europe, Middle East, Africa, and Canada. Dr. Christiansen directed wide-ranging operations leading over 10,000 employees involved in a myriad of business functions spanning clinical research, regulatory compliance, manufacturing, logistics, sales & marketing, business strategy, and risk management. His extensive experience in amalgamating and optimizing a diverse workforce from numerous dissimilar cultures produced revenue of over $10 billion USD which accounted for 25% of Merck’s overall business. Dr. Christiansen holds a Doctor of Medicine degree from the University of Copenhagen in Denmark.

Approved By A Shark

“I like what Pepex® is doing so much that I invested in it, and now, you can too!”

—Kevin Harrington, Original Shark On Shark Tank

FAQs

Explore the answers to some of our more frequently asked questions.

Pepex proprietary biosensor technologies, referred to individually as Composite Conductive Monofilament (CCM®), 3 Electrode (3E™), and Lansing Sensor (LS®), and  collectively as Pepex Biosensor Technologies (PBT), are capable of identifying hundreds of unique biomarkerswhich indicate the presence, and in some cases the concentration level, of cancers, lactic acid, sepsis, Alzheimer’s, HIV, Ebola, hepatitis, Traumatic Brain Injury (TBI), tuberculosis, CV-19, and other life-altering conditions quickly, easily, and cost effectively in saliva, blood, and interstitial fluid.

Pepex and TheraSense, Inc., an affiliated company created to commercialize technology created by a joint team of researchers, were founded in 1995 as a joint venture effort by Dr. Heller of the University of Texas. During the ensuing 9 years, approximately $100MM was invested to sponsor biosensor technology development efforts, the result of which was the originalFreeStyle® Libre® branded blood glucose monitoring system. After a highly successful product launch, in 2004 TheraSense was acquired for over one billion dollars by Abbott Labs while Pepex retained usage rights to all IP developed to that point, as well as a core staff of researchers and developers.  Since 2004, Pepex raised significant additional funding that supported conducting over 35,000 documented experiments producing over 300 global patents that protect its proprietary manufacturing processes and biosensor designs.

• Accuracy – produces +98% sensitivity and specificity
• Timeliness – diagnostic results in seconds to minutes
• Cost Effectiveness – typically less than $10.00/unit
• Ease of Use – self-administered/disposable options
• Versatility – configurable for single use, continuous monitoring, catheter & in-line form factor applications

With adequate financial resources, Pepex plans to pursue commercialization efforts targeting those specific use cases which offer the greatest ROI opportunity based on key quantifiable criteria including short/long-term revenue potential, projected time to market, prospective customer level of interest, and probability of successful outcome. The projected lead time to deliver functional prototypes for specific use cases is approximately 4-6 months, assuming the associated biomarker or analyte is clearly defined. Moving forward, Pepex intends to be the sole source provider of PEEK fiber installed in a customer-specified form factor, and capable of assisting partners with requisite design for manufacturing (DFM), pilot production, full-rate manufacturing, and high-volume assembly, as required.

For investment opportunities in Pepex® Biomedical and its groundbreaking biosensor technology, interested parties can contact our investor relations team or visit our website for more information on available investment options.

A biological marker (biomarker) is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions.  Biomarkers have various applications, such as risk estimation, disease screening and detection, diagnosis, estimation of prognosis, prediction of benefit from therapy, and disease monitoring.

An analyte is a substance or molecule that is being analyzed or studied in a laboratory setting. It can refer to any type of molecule, including drugs, hormones, proteins, or other biological compounds. The term analyte is commonly used in the fields of chemistry, biochemistry, and clinical laboratory science to refer to the substance being measured or tested.  The analysis of an analyte can be performed using a variety of techniques, including spectrophotometry, chromatography, and mass spectrometry. The specific method used will depend on the type of analyte being studied and the desired information being sought.  The measurement of analytes is important in a variety of fields, including medical diagnostics, environmental monitoring, and quality control. In the medical field, for example, the measurement of analytes such as glucose, cholesterol, and electrolytes can provide important information about a patient’s health and assist in the diagnosis and treatment of various conditions.

Artificial intelligence, or AI, is technology that enables computers and machines to simulate human intelligence and problem-solving capabilities.  On its own or combined with other technologies (e.g., sensors, geolocation, robotics) AI can perform tasks that would otherwise require human intelligence or intervention.  As a field of computer science, artificial intelligence encompasses (and is often mentioned together with) machine learning and deep learning. These disciplines involve the development of AI algorithms, modeled after the decision-making processes of the human brain, that can ‘learn’ from available data and make increasingly more accurate classifications or predictions over time.

In recent years, an emerging class of manufacturing techniques has become available which offers significant cost, time and quality benefits across a broad spectrum of industries. These new techniques are collectively known as additive manufacturing. During additive manufacturing, material is deposited layer by layer to build up structures or features. This is in contrast to traditional subtractive manufacturing methods where masking and etching processes are used to remove material to get to the final form. Advantages of additive manufacturing processes include direct CAD-driven, art-to-part processing, which eliminates expensive hard-tooling, masks, and vertical/horizontal integration, which lead to fewer overall manufacturing steps.

Design for manufacturing (DFM) is a product design ideology that focuses on creating a better design at a lower cost by optimizing the selection of materials and manufacturing processes. Following these guidelines, the final product should be easier to manufacture, and the production should take less time when compared to the original design. DFM also incorporates the use of new ideas and techniques to bring about a positive change in product design to benefit all the involved parties (designer, manufacturer, and customer).. Design for manufacturing focuses on minimizing the complexities involved in manufacturing operations as well as reducing the overall part production cost. The principles involved in DFM are standardizing of materials and components, minimizing part counts, designing for efficient assembly, simplifying and reducing the number of manufacturing operations and creating modular assemblies, while the process involved in DFM includes raw material selection and review, secondary processes if any, dimensional and other requirements, and final packaging.

Aerosol Jet printing is a breakthrough manufacturing technology that is an emerging replacement for traditional thick-film processes like screen-print, photolithography and micro-dispensing, as well as being far more capable than inkjet. The aerosol jet printing process utilizes an aerodynamic focusing technology to produce electronic and physical structures with feature sizes as small as 5 microns and can also produce wide area conformal coatings. Aerosol jet printing supports a wide variety of materials, including nanoparticle inks and screen-printing pastes, conductive polymers, insulators, adhesives, and even biological matter.

A Nanoparticle is an ultrafine unit with dimensions measured in nanometers (nm; 1 nm = 10−9 meter). Nanoparticles exist in the natural world and are also created as a result of human activities. Because of their submicroscopic size, they have unique material characteristics, and manufactured nanoparticles may find practical applications in a variety of areas, including biomedicine, engineering, manufacturing, catalysis, and environmental remediation.

PEEK fiber (Polyetheretherketone) is a thermoplastic polymer available in various forms, including multifilament, monofilament, and spun yarns. It offers excellent mechanical properties that are maintained even under extreme conditions. PEEK also has unique properties like total biocompatibility, UV resistance, pure radiolucency, gamma-ray resistance, and low/no toxicity in all forms. These properties allow PEEK plastic to be implemented in many engineering applications, from automotive engine parts to medical implants, bearings, chemical equipment, and even radioactive applications.

A contract development and manufacturing organization, or CDMO, provides end-to-end, fully integrated product development and manufacturing solution to biotechnology and medical device companies. Specifically, a medical device CDMO offers its clients the ability to scale up faster, accelerate revenue and time to market, and deliver greater product value which provides acompetitive advantage for medtech companies through vertical integration of the product value chain. Furthermore, a CDMO serves as a real collaborative partner in the product developmentand manufacturing processes, including product optimization, as they work with customers on the journey from discovery to commercialization and beyond.

Ready To Invest In Pepex® Biomedical?

Are you prepared to take action and contribute to improving the world through technology and innovation? Click the button below to begin!

Copyright 2024 Pepex® Biomedical. All Rights Reserved.